The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Celltrion/Nippon Kayaku Herceptin Biosimilars Get OK for New Breast Cancer Dosing Schedule
Celltrion Healthcare Japan and Nippon Kayaku said on August 21 that their biosimilar versions of Herceptin (trastuzumab) were approved for a new, more commonly used dosing schedule for breast cancer, eliminating the only difference they had versus Chugai Pharmaceutical’s originator.…
To read the full story
Related Article
- Nippon Kayaku Forecasts 4.3 Billion Yen Full-Year Sales for Biosimilars
November 11, 2019
- Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
November 29, 2018
- Celltrion Launches Herceptin Biosimilar in Japan
August 29, 2018
- Japan’s 1st Herceptin Biosimilar Now Available, but Use Limited to Gastric Cancer
August 21, 2018
BUSINESS
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
- Boehringer Passes on Option for Nxera’s Schizophrenia Program
December 22, 2025
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…